TABLE 1

Demographics and baseline patient characteristics for patients treated with oral corticosteroids for COPD exacerbations in a primary-care setting (Cohort 1) and in a hospital setting (Cohort 2)

VariableCohort 1Cohort 2
Subjects641610 245
Age years71.3±10.375.1±9.9
 ≥40–<60 years850 (13.2)716 (7.0)
 ≥60–<80 years4113 (64.1)5838 (57.0)
 ≥80 years1453 (22.6)3691 (36.0)
Male3011 (46.9)5258 (51.3)
Smoking status#
 Nonmissing6364 (99.2)10,169 (99.3)
 Never-smoker747 (11.7)993 (9.8)
 Current smoker2044 (32.1)2940 (28.9)
 Ex-smoker3573 (56.1)6236 (61.3)
BMI# kg·m−227.6±6.126.0±6.2
 Nonmissing1769 (27.6)8943 (87.3)
 <18.5 kg·m−2331 (5.4)766 (8.6)
 ≥18.5–<25 kg·m−22045 (33.1)3596 (40.2)
 ≥25–<30 kg·m−21948 (31.5)2495 (27.9)
 ≥30 kg·m−21855 (30.0)2086 (23.3)
Active asthma866 (13.5)486 (4.7)
Active rhinitis114 (1.8)493 (4.8)
Active eczema267 (4.2)430 (4.2)
Nasal polyps+133 (2.1)147 (1.4)
Diabetes mellitus+1132 (17.6)1881 (18.4)
GORD+1426 (22.2)2044 (20.0)
Cardiovascular disease+3001 (46.8)6414 (62.6)
Hypertension+3019 (47.1)4886 (47.7)
Osteoporosis+695 (10.8)1241 (12.1)
Depression/anxiety+2713 (42.3)4396 (42.9)
FEV1 % pred53.9±20.150.9±20.9
 Subjects58737883
 ≥80% pred637 (10.8)771 (9.8)
 ≥50%–<80% pred2734 (46.6)2901 (36.8)
 ≥30%–<50% pred1776 (30.2)3046 (38.6)
 <30% pred726 (12.4)1165 (14.8)
GOLD group
 Subjects54608789
 A838 (15.3)556 (6.3)
 B768 (14.1)701 (8.0)
 C1827 (33.5)3641 (41.4)
 D2027 (37.1)3891 (44.3)

Data are presented as n, mean±sd or n (%), unless otherwise stated. BMI: body mass index; GORD: gastro-oesophageal reflux disease; FEV1: forced expiratory volume in 1 s; GOLD: Global Initiative for Chronic Obstructive Lung Disease. #: the closest BMI within 10 years of the index date, and the smoking status closest to and within 5 years of index date were included; : active disease was defined as a diagnostic or monitoring read code or evidence for specific treatment within 1 year before index date; +: ever diagnosed.